The HCPLive Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.
May 5th 2024
Treatment-resistant depression with intranasal esketamine was linked to improvements in major depressive disorder (MDD) symptoms and fibromyalgia pain in a 40-year-old female.
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Advances In™ Schizophrenia: Expanding the Therapeutic Landscape
View More
Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia
View More
Southern California Psychiatry Conference
September 13-14, 2024
Register Now!
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Updates on New and Emerging Therapies to Improve Outcomes for Patients With Major Depressive Disorder
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
2023 Annual Psychiatric Times™ World CME Conference
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Real Psychiatry 2025
January 2025 - Exact Date TBA
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Psychologically Distressed Patients Faced Challenges During COVID-19
February 8th 2024According to a new study, overall outpatient mental health care increased from 11.2% to 12.4% between 2018 and 2018. However, for individuals with serious psychological distress, the rate of care decreased from 46.5% to 40.4%.
Antidepressants from SSRI or SNRI Classes Were Safe for Most Stroke Survivors
February 2nd 2024Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.
Transgender, Gender Diverse People More Likely to Have Unmet Mental Health Needs
February 1st 2024In a survey, 1 in 6 cisgender men and women reported unmet mental health needs at their latest visit with a healthcare professional. Mental health needs for other gender identities ranged from 1 in 5 and 1 in 4.
Antipsychotic Injections for Schizophrenia Linked to Decline in Hospital Readmissions
January 31st 2024In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections.
CBT May Normalize Fronto-Parietal Activation in Unmedicated Pediatric Anxiety
January 30th 2024After undergoing cognitive behavioral therapy, unmedicated pediatric patients with anxiety disorder experienced changes in activation in the fronto-parietal network regions including left and right supplementary motor area, middle frontal gyrus, and superior parietal lobule.
Single Substance Not Linked to Single Psychiatric Symptom in Adolescents
January 29th 2024A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.
Behavioral Activation Therapy Treats Depression in Patients with Heart Failure
January 26th 2024A new study found behavioral activation therapy is just as effective as antidepressants for treating depressive symptoms in patients with heart failure, with both treatments having a 50% reduction at months 3, 6, and 12.
Jacob Ballon, MD, MPH: Discusses Takeaways from Studying Long-Term Olanzapine and Samidorphan
January 17th 2024In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.
Increase in Depressive Symptoms Linked to Further Weight Gain in Overweight, Obesity
January 11th 2024For every increment increase in a participant’s usual score for depressive symptoms, investigators of a new study found weight increased a month later by 45g, only for participants with overweight and obesity.